MedTrace Logo

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

NCT03272711 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2020-01-14

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.

Conditions

  • Age-related Cognitive Decline

Interventions

DRUG

Vortioxetine 10 mg

BEHAVIORAL

Cognitive training program

Online training program, 30 minutes a day, 5 times a week

Sponsors & Collaborators

  • Queen's University

    collaborator OTHER

  • Takeda

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Eric Lenze, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-01-24
Completion
2019-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272711 on ClinicalTrials.gov